Ozekibart's 52% Reduction in Risk Sparks 70% Jump Amid Concerns Over Liver Safety
- Inhibrx Biosciences’ ozekibart showed 52% reduced disease progression risk in chondrosarcoma, driving a 70% post-market stock surge. - Combination trials in colorectal and Ewing sarcoma showed 23%–64% response rates, suggesting broader oncology potential. - Hepatotoxicity concerns led to monitoring strategies, reducing adverse events to 11.8% in ozekibart group. - Company plans 2026 BLA submission; stock surged 63% pre-market after prior 10% decline.
Shares of Inhibrx Biosciences (NASDAQ:INBX) soared by more than 70% in after-hours trading on October 23, 2025, after the company announced encouraging Phase 2 trial data for its investigational cancer therapy ozekibart (INBRX-109) in chondrosarcoma, a rare and aggressive bone malignancy that currently lacks approved systemic treatments, as reported by an
Ozekibart’s safety profile was generally acceptable, though liver toxicity was identified as a significant issue. Early in the study, a fatal liver-related incident led to the adoption of risk mitigation strategies, including excluding patients with advanced liver dysfunction and closely monitoring liver function during the initial treatment cycles. These interventions reduced the rate of treatment-related liver side effects to 11.8% in the ozekibart group versus 4.5% in the placebo group, with most cases being mild or moderate in severity, as detailed in
In addition to chondrosarcoma,
The company intends to file a Biologics License Application (BLA) with the U.S. Food and Drug Administration in the second quarter of 2026, according to Investing.com. Comprehensive data from the ChonDRAgon study will be presented at the Connective Tissue Oncology Society Annual Meeting on November 14, 2025, as noted by Tokenist.
The market responded strongly to the announcement, with
Financially, Inhibrx has a market capitalization near $457 million and maintains strong liquidity, with a current ratio close to 5, according to
INBX shares have climbed 140% year-to-date, reflecting strong investor confidence, though some warn that commercial success will depend on overcoming regulatory challenges and proving long-term effectiveness. With no approved therapies for chondrosarcoma, ozekibart’s potential to be first to market has drawn parallels to other breakthrough drugs in specialized oncology fields, according to Stocktwits.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bitcoin News Update: Crypto Recovery After Crash: Risky Presale Opportunities or Institutional Investment?
- Post-crash crypto rebound sees investors favoring projects with strong fundamentals and high-growth presales like BullZilla, Blazpay, and DeepSnitch AI. - Ethereum rebounds to $3,941.73 amid institutional confidence in Layer-2 upgrades and DeFi dominance, while BNB surges 6% post-CZ pardon. - High-risk presales offer asymmetric returns: $100 in DeepSnitch AI could yield $10,000 if token hits $2 post-launch. - Bitcoin Hyper aims to enhance Bitcoin's scalability via Solana integration, raising $24.4M for Q

XRP News Today: XRP Whales Sell 70M, Retail Investors Drive Price Up by Absorbing Supply
- XRP whales sold 70M tokens in two weeks, yet price rose to $2.55 amid retail/institutional buying. - Whale holdings increased (12.65% at 1M-10M range) while futures funding rates turned positive, signaling bullish sentiment. - Technical indicators show bullish reversal patterns, but price remains below 50-day SMA and faces $2.60 resistance. - Regulatory delays (SEC ETF decisions) and macro risks persist, though institutional demand stabilizes via Evernorth's $1B Nasdaq listing plan.
Solana Latest Updates: Optimism for Solana ETF Faces Challenges Amid Waning Momentum as $200 Approaches
- Solana's price hovers near $183 amid speculation about potential U.S. spot-SOL ETF approval following Hong Kong's regulatory green light. - Technical analysis shows mixed signals: a $200 breakout could drive momentum toward $230–$300, while support below $175 risks a pullback to $160–$165. - Despite 85% bullish community sentiment and institutional adoption potential, declining on-chain activity and regulatory uncertainties cloud near-term outlook. - Upcoming Solana Breakpoint conference in December will

LinkedIn co-founder Reid Hoffman acquires CryptoPunk PFP
